Komori
Kissei Pharmaceutical (4547) · PolicyAdvanced

Strengthening Governance to Enhance Corporate Value and Achieve Sustainable Growth

First written in FY2016. 5 of 10 entries say "Advanced", first in FY2020. Latest entry: FY2026.

10entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019AdvancedFY2020 – FY2022RestatedFY2023-Q1AdvancedFY2024 – FY20262016: 120162017: 120172018: 120182019: 120192020: 120202021: 020212022: 220222023: 020232024: 120242025: 020252026: 22026
Same theme, other companies
Governance focused on shareholder rights, social trust and sustainable growthA theme 124 companies write about · 0 as a headwind · 125 as a tailwind

24 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 124 companies compared. The sentences above are computed from all 124.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「12 men, 4 women (women account for 25.0% of officers)」

    The company plans for women to account for 25.0% of officers following the annual general meeting of shareholders, indicating a plan to increase diversity from 12.5% as of the filing date.
  2. 2026-06-01AdvancedGeneral Meetings of Shareholders

    「In executing duties delegated by the Board of Directors, our management structure is designed to strengthen management, increase agility and further enhance management capabilities, with the representative director and chair, the Chief Executive Officer (CEO), overseeing overall management and the representative director and president, the Chief Operating Officer (COO), responsible for executing the business as a whole.」

    The disclosure covered the division of overall management and executive responsibilities between the CEO and COO, as well as the Board of Directors structure, including 4 outside directors.
  3. FY2024AdvancedAnnual report

    「In addition, we have established 3 committees directly under the Board of Directors: (a) Risk Management Committee, (b) Compliance Committee, and (c) Sustainability Promotion Committee.」

    In addition to risk management and compliance, the company has positioned the Sustainability Promotion Committee as an advisory body directly under the Board of Directors, giving specific form to its governance structure.
  4. FY2023-Q1RestatedAnnual report

    「There were no material changes during the cumulative first quarter of the current fiscal year to the management policies, management strategies or other matters established by the Group.」

    This filing contains no description of any significant changes to the governance policy.
  5. FY2022AdvancedAnnual report

    「In light of rapid changes in the business environment, we introduced an executive officer system in June 2022 to further strengthen corporate governance and establish a more flexible business execution structure.」

    The company introduced an executive officer system in June 2022, adding a more flexible business execution structure. It also reported 4 outside directors and 2 outside corporate auditors as independent officers.
  6. FY2020AdvancedAnnual report

    「To enhance corporate value and achieve sustainable growth as a company with a meaningful purpose and value, we have positioned the enhancement and strengthening of corporate governance as one of our important management priorities. …In addition, 3 outside directors and 2 outside corporate auditors have been designated and reported to the Tokyo Stock Exchange as independent officers in accordance with its rules.」

    The company described a structure that reconfirmed its policy of strengthening governance and reported 3 outside directors and 2 outside corporate auditors as independent officers.
  7. FY2019RestatedAnnual report

    「To enhance corporate value and achieve sustainable growth as a company with a meaningful purpose and value, we have positioned the enhancement and strengthening of corporate governance as one of our important management priorities.」

    The company has reaffirmed its policy of enhancing and strengthening governance to enhance corporate value and achieve sustainable growth.
  8. FY2018RestatedAnnual report

    「To enhance corporate value and achieve sustainable growth as a company with a meaningful purpose and value, we have positioned the enhancement and strengthening of corporate governance as one of our important management priorities.」

    The company has reaffirmed its policy of enhancing and strengthening governance to enhance corporate value and achieve sustainable growth.
  9. FY2017RestatedAnnual report

    「To enhance corporate value and achieve sustainable growth as a company with a meaningful purpose and value, we have positioned the enhancement and strengthening of corporate governance as one of our important management priorities.」

    The company has reaffirmed its policy of making the enhancement and strengthening of corporate governance an important priority in order to enhance corporate value and achieve sustainable growth.
  10. FY2016First statedAnnual report

    「To enhance corporate value and achieve sustainable growth as a company with a meaningful purpose and value, we have positioned the enhancement and strengthening of corporate governance as one of our important management priorities.」

    The company has adopted a structure combining decision-making and oversight by the Board of Directors, outside officers and the statutory auditor system.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 5 of its 10 moves.

555533★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages5×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval5×
  4. 3Promoting overseas expansion and stabilizing the overseas earnings base5×
  5. 4Stable dividends and profit allocation in line with earnings5×
  6. 5Sustainable Growth as a Drug Discovery-Focused R&D Company3×
  7. 6Creating New Drugs Through Development Pipelines and External Partnerships3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-06-01: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Governance to Enhance Corporate Value and Achieve Sustainable Growth | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori